Sanofi digs deep to buy US hemophilia specialist Bioverativ for $11.6 billion

The French drugmaker is nearing a deal to acquire biotechnology company Bioverativ for $105 a share.

from Mergers and Acquisitions http://ift.tt/2DweOCr